Lucienne Ronco, PhD, FSHD Society
The international FSHD advocacy drum is beating loudly with an important and consistent message, recently reinforced by FSHD Europe on behalf of national FSHD patient organizations across Europe. In their new publication in Neuromuscular Disorders, Facioscapulohumeral muscular dystrophy: revisiting three prevailing assumptions through the perspective of FSHD Europe (de Haas et al.), the authors draw on extensive engagement with the patient community and participation in international initiatives. The result echoes the advocacy messages shared by people with FSHD around the world.
FSHD is a disease spectrum. Onset can occur at any age, from childhood to late adulthood, and its impact ranges from mild weakness to severe disability.
FSHD is a progressive disease with a highly variable course. Symptoms worsen over time, but the rate and pattern of muscle loss differ from person to person. This unpredictability creates significant uncertainty and anxiety, making it difficult for individuals to plan their lives and make informed decisions about their future.
Meaningful care options exist today. Symptomatic care, like appropriately targeted exercise and nutrition, can support muscle maintenance in the face of ongoing muscle loss driven by DUX4. Multidisciplinary care that addresses functional impairment, respiratory and sleep involvement, pain, and fatigue provides meaningful treatment and support. While disease-modifying therapies are being researched and developed, personalized, multidisciplinary care remains central to optimizing quality of life.
Thank you, FSHD Europe, for keeping these messages alive and central to supporting crucial patient care!